2021/12/4  
Medigen turns from loss to profit in Q3, with EPS of NT$3.22 (2021/11/24)
其它新聞 Other News   
  • China plans to blacklist more ‘diehard Taiwan secessionists’
  • US invites Taiwan to Summit for Democracy; China, Russia, Vietnam excluded
  • Third televised forum: KMT, DPP clash over concurrent referendums and elections
  • New Taipei City Hall rooftop to open doors to the public for the first time
  • Companies plan to increase salaries next year, up to 4% in technology sector
  • Raw material and energy prices to continue rising till year end: expert
  • More Pfizer doses allocated to meet surging demand
  • East coast small farmers go digital, putting local delicacies on online platforms
  • ‘American Girl’ carries high hopes with seven Golden Horse nominations
  • National Taiwan Normal University overhauls school anthem
  • 英文 English 
    Medigen turns from loss to profit in Q3, with EPS of NT$3.22 (2021/11/24)

    Taiwanese vaccine developer Medigen presented good news at its investor conference on Wednesday. It's turned a profit for the first time in its three plus years on the Taipei Exchange. It's also in the final stage of talks with the EU, over conducting Phase III human trials for its COVID vaccine. A permit may be granted as early as next year in the first quarter.

    Leo Lee
    Medigen executive VP
    Our third quarter financial report went from loss to profit. With successive deliveries to go out in the fourth quarter, we’re expecting even stronger results. Regarding the inspection and registration process in the EU, we are now in the final stage of talks with the EU. It shouldn’t be much longer before we can begin Phase III trials using the immunobridging approach, under the guidance of the EU.

    Medigen's vaccine is already being tested in Paraguay. Results from the ongoing Phase III trial are due next January. The vaccine was also chosen for the World Health Organization's Phase 3 Solidarity Trial. Results from that study are due early next year.
    中文 Chinese  
    高端轉虧為盈! EPS3.22元 稅後純益達6.8億元

    高端出席法說會,執行副總李思賢宣布好消息,公司第三季首度轉虧為盈,目前也積極布局歐盟的三期臨床試驗,最快明年第一季可以拿到藥證。

    [[高端疫苗執行副總 李思賢]]
    “我們第三季的財報已經正式轉正了,第四季隨著陸陸續續交貨,會有更亮眼的成績。有關歐盟的查驗登記進展,我們跟歐盟已經談到最後的階段,相信不久的將來就會啟動用免疫橋接的方式,在歐盟的指導之下,去進行三期的臨床試驗。”

    高端22號取得澳洲審查資格認定,股票一度飆到228元漲停,今天以240元收盤。目前,除了在巴拉圭進行第三期臨床試驗,預計12月受試者可打完第二針,明年1月初會有報告。另外,高端10月底被選入WHO試驗疫苗,明年第一季也會有結果出爐。
    關於民視 常見問題 如何收看民視 意見信箱

    © 2009 FTV All Rights Reserved 版權所有‧盜用必究 Designed by FTV
    地址:244 新北市林口區信義路99號   觀服電話:(02)8601-8601 服務時間:週一至週日09:00-21:00   傳真:(02)8601-3955

    本網站使用 cookie 與其他技術為您提供更好的使用體驗, 請閱讀我們的的隱私權政策,通過使用我們的網站,表示您確認並同意我們的政策。